- Home
- MRSN vs OXSQ Comparison
MRSN vs OXSQ Comparison
Compare MRSN & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- OXSQ
- Stock Information
- Founded
- MRSN 2001
- OXSQ 2003
- Country
- MRSN United States
- OXSQ United States
- Employees
- MRSN N/A
- OXSQ N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- OXSQ Blank Checks
- Sector
- MRSN Health Care
- OXSQ Finance
- Exchange
- MRSN Nasdaq
- OXSQ Nasdaq
- Market Cap
- MRSN 230.0M
- OXSQ 185.5M
- IPO Year
- MRSN 2017
- OXSQ N/A
- Fundamental
- Price
- MRSN $2.21
- OXSQ $2.70
- Analyst Decision
- MRSN Buy
- OXSQ
- Analyst Count
- MRSN 6
- OXSQ 0
- Target Price
- MRSN $6.00
- OXSQ N/A
- AVG Volume (30 Days)
- MRSN 1.1M
- OXSQ 431.2K
- Earning Date
- MRSN 11-13-2024
- OXSQ 11-05-2024
- Dividend Yield
- MRSN N/A
- OXSQ 15.56%
- EPS Growth
- MRSN N/A
- OXSQ N/A
- EPS
- MRSN N/A
- OXSQ N/A
- Revenue
- MRSN $34,837,000.00
- OXSQ $44,787,853.00
- Revenue This Year
- MRSN N/A
- OXSQ N/A
- Revenue Next Year
- MRSN $7.15
- OXSQ N/A
- P/E Ratio
- MRSN N/A
- OXSQ N/A
- Revenue Growth
- MRSN N/A
- OXSQ N/A
- 52 Week Low
- MRSN $1.22
- OXSQ $2.67
- 52 Week High
- MRSN $6.28
- OXSQ $3.29
- Technical
- Relative Strength Index (RSI)
- MRSN 51.26
- OXSQ 24.79
- Support Level
- MRSN $2.12
- OXSQ $2.87
- Resistance Level
- MRSN $2.83
- OXSQ $2.96
- Average True Range (ATR)
- MRSN 0.24
- OXSQ 0.05
- MACD
- MRSN 0.03
- OXSQ -0.02
- Stochastic Oscillator
- MRSN 39.81
- OXSQ 10.31
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing, and Diversified Insurance.